Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure

    NEXT STORY
    Oncology Venture increases its ownership in dovitinib
    PREV STORY
    The Three Strategies of Individual Patient Engagement
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Dr. Jeffrey L. Craig Elected to the American Health Council’s Physician Board

    NEW YORK, Sept. 28, 2017 (GLOBE NEWSWIRE) -- The American Health Council is proud ...

    author_avatar
    NASDAQ Market News

    Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)

    author_avatar
    NASDAQ Market News

    ADMA Biologics Expands Global Regulatory Approval Presence and Announces FDA Approval to Commence Hepatitis B Plasma Collections

    author_avatar
    NASDAQ Market News